Today, we’ve packed the conference center at a downtown hotel with over 400 guests.

The speakers include James Altucher, Chris Campbell, Zach Scheidt, Ray Blanco and more!

On the agenda:

• AI-Powered Biotech Breakthroughs
• The AI Income Playbook: 3 Powerful Cash Flow strategies
• The New “Mag 7” Before the Mainstream Catches On
• And much, much more!

I’m your boots-on-the-ground reporter for this event.

(Yes, I’m very much writing this in the back of the conference room in real-time.)

Today, I’m sharing my notes from Baltimore for those of you that couldn’t attend in person.

Let’s start with a timely investment idea:

Note #1: Income Guru Zach Scheidt’s Newest Buy Opportunity

According to Zach, now is a GREAT time to be investing in dividend stocks.

Here’s why…

Say you’re earning 4% today in a high-yield savings account.

Unfortunately, this high rate won’t last long as the Fed’s lowering cycle continues. As interest rates decline, that 4% rate you’re earning will decline as well.

As this happens, companies paying high dividends will prove more attractive to investors.

So expect money to move out of high-yield accounts and into high-quality dividend paying stocks in the near future.

According to Zach, dividend stocks should also benefit from any rising uncertainty in the U.S. economy and around the world.

Any sort of volatility stemming from the election, China, hiccups in the AI revolution, and more should benefit dividend stocks as investors seek safe places to park money.

Note #2: Ray Blanco’s AI Biotech Breakthroughs

AI and machine intelligence have been transforming the way we discover and develop new drugs.

By using computational biology and artificial intelligence, companies are helping biopharmaceutical companies pick winning drug candidates and accelerate the drug development process.

Despite everything we’ve learned about human biology, chemistry, and how to build new drugs, the discovery and development process is still fraught with extreme risk and high rates of failure.

Maybe only one in one thousand drug candidates succeed in making their way from discovery to commercialization.

Even drugs that are deemed “good enough” for expensive clinical trials have abysmal success rates.

Less than 10% of Phase 1 drugs make it to approval, and even drugs that make it to Phase 3 have failure rates in the range of 70%.

Accounting for the high cost of failures, the price tag of getting a new drug to market can approach $2 billion in a process that can take a decade or more.

That's where computational biology and artificial intelligence can help pick winners and streamline the regulatory process.

Suffice it to say, there’s plenty of innovation and advancements in technology to be excited about right now.

Note #3: James Altucher Ended the Great Financial Crisis

On a lighter note, James Altucher began the conference today with a fantastic welcome speech.

He spoke about living in the only residential building on Wall St. in New York City.

This was in 2009, years after he walked away from managing a hedge fund to focus on his other passions.

He could see the entrance to the New York Stock Exchange from his doorstep.

For weeks in early 2009, he noticed the dismal attitudes of traders on their way to work in the morning.

(After all, this was the height of the Great Financial Crisis.)

So James – in true James fashion – took it upon himself to cheer up this somber bunch.

One morning James went outside with bags of candy – M&Ms, Hershey Bars, and Kit Kat Bars.

(Yes, this is a true story.)

He stood at the entrance of the NYSE and passed out candy to traders walking to work in the morning – doing his part to cheer the sad looks off their faces.

That day was March 9th, 2009, the exact day the stock market bottomed during the Great Financial Crisis.

“Your welcome” James said at the end of his story.

I’ll try to get you live footage from James’ speeches in tomorrow’s alert.

Plus, I’ll have plenty more to share from today’s event.

In fact, I didn’t even get to the best part!

Seven of our top experts just sat down to pick the next “Magnificent 7” – AKA the next wave of technology stocks that will dominate the tech world.

Tune in tomorrow to hear their best picks.